Background {#Sec1}
==========

Community acquired pneumonia (CAP) is one of the most common causes of morbidity and mortality worldwide \[[@CR1]\] and *Streptococcus pneumoniae* (SP) has been found to be its most common pathogen \[[@CR2]\]. The frecuency of pneumococcal pneumonia might be decreasing following widespread use of the 13-valent pneumococcal vaccine in children, and in people 65 years of age or older \[[@CR3]\].

Disease caused by SP is a major public health problem worldwide, leading to invasive CAP, meningitis, and bacteremia. Non-invasive illnesses, such as non-bacteremic pneumonia, otitis media, bronchitis and upper airway infections are common but less severe \[[@CR4]\]. Besides its role as a pathogen, SP is asymptomatically carried in the nasopharynx by up to 50% of infants and up to 5% of adults \[[@CR5]\]. Colonization occurs before disease, and transmission is from child to child and from children to adults can occur \[[@CR6]\]. In addition to the traditional microbiological diagnosis of pneumonia based on respiratory specimens and blood culture, the use of immunochromatographic SP urinary antigen test (SPUAT) in patients with CAP is also recommended for diagnosis by international guidelines \[[@CR7]\]. Sensitivity and specificity of SPUAT in adults for the etiologic diagnosis of pneumococcal CAP have been found to be 57.9--75% and 96.6--99.7%, respectively \[[@CR8]--[@CR11]\]. Antibodies to capsular polysaccharide antigen provide serotype-specific protection against serious infection, and the pneumococcal vaccines are designed to cover the serotypes most commonly associated with severe pneumococcal disease \[[@CR12]\]. Vaccination has greatly reduced the burden of pneumococcal disease.Two types of pneumococcal vaccines are available in Argentina (country where this study was performed): the 23-valent pneumococcal polysaccharide (non-conjugate), (PPV23) and the 13-valent polysaccharide conjugate vaccine (PCV13).

By 2016, the national committee on immunizations in Argentina (CoNain) recommended the PPV23 for all individuals ≥65 years of age and for those younger, with comorbidities. Universal PCV13 vaccination for children was initiated in Argentina in 2012 \[at 2, 4 and 6 months and 1 year of age (3 + 1 schedule)\], with a coverage higher than 90% \[[@CR13]\]. Results of the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA), a randomized controlled trial in elderly adults in the Netherlands, demonstrated the efficacy of PCV13 to prevent IPD and pneumonia caused by homologous serotypes \[[@CR14]\]. A decline in the incidence of pneumococcal pneumonia in adults has been observed after PCV13 introduction in children, indicating an early indirect protection (so called herd effect) on adult disease, as a consequence of childhood vaccination \[[@CR15]\]. These effects may accrue over the coming years with implications for national pneumococcal vaccination policies in adults.

Objectives {#Sec2}
==========

To compare the SPUAT result (a sensitive and highly specific test to detect pneumococcal infection), the clinical findings and outcomes, in patients with CAP admitted during two different periods of time: 2001--2002 (CAP1) and 2015--2016 (CAP2), trying to define if there were any differences in the frequency and clinical features of pneumococcal CAP during these two periods.

Methods {#Sec3}
=======

Patients {#Sec4}
--------

The cases eligible for the study were adults over 17 years-old, with CAP (which met the inclusion criteria described below), consulting the Emergency Department or admitted to the wards of the Department of Medicine and the critical care areas of the Hospital de Clínicas, University of Buenos Aires, from January 1st 2015 to December 31st, 2016. The controls were patients admitted to the same institution from January 1st 2001 to December 31st, 2002. Cases and controls were evaluated in an identical fashion during the two periods of time. The criteria published in a National Clinical Practice Guideline were applied in decision making about the site of care to the patients who were admitted (Table [1](#Tab1){ref-type="table"}) \[[@CR16]\]. Inclusion criteria were: having a presumptive diagnosis of pneumonia within the first 24 h of admission to the study; presence of a new infiltrate on chest radiograph, and clinical findings confirmatory of at least one "major criterion" such as cough, sputum, or fever \> 37.8C; or at least two "minor criteria", including pleuritic chest pain, dyspnea, altered mental status, findings consistent with consolidationon physical exam, and leukocyte count \> 12,000/ mm^3^ \[[@CR17]\]; having had testing for the detection of SPUAT and blood cultures during their initial microbiological evaluation at admission. SPUAT was carried out from freshly obtained urine samples according to the manufacturer's instructions (results read visually at 15 min and recorded as positive, with no interpretation of color intensity, or negative). All samples were stored at ≤ − 70 °C and assayed later, directly after thawing, Exclusion criteria included: having been hospitalized for any reason within the previous 14 days; no chest radiographic confirmation of a new infiltrate or attributing the abnormality only to a noninfectious etiology; a confirmed diagnosis of lung cancer before admission to the study; patients with a known diagnosis of HIV at the time of enrollment, or high doses of immunosuppressants (\> 20 mg of prednisone or other corticosteroid dose equivalent) in chronic treatment (over 20 days).Table 1Criteria for hospital admission, Luna CM, et al. \[[@CR16]\]1) Presence of two or more of the following: age \> 65 years; chronic pulmonary disease; congestive heart failure; chronic kidney failure; chronic liver disease; malignant neoplasm; diabetes mellitus; hospitalization for pneumonia during the past year.\
2) Respiratory rate ≥ 30 / minute.\
3) Low blood pressure: systolic \< 90 and/or diastolic: \< 60 mmHg).\
4) Poor respiratory mechanics. (paradoxical respiration. Circulation. etc.).\
5) Any of the following: PaO~2~ \< 60 mmHg; SaO~2~ \< 89%; PaCO2 \> 50 mmHg with acidosis; white blood cell count \< 4000 or \> 30.000/mm^3^; BUN \> 25 mg/dl; hematocrit \< 30%.\
6) Alteration of consciousness.\
7) Serious swallowing disorder suggesting likely aspiration.\
8) Suppurative complications (pericarditis. Arthritis. empyema. Etc.)\
9) Severe chest radiograph involvement (multilobar, bilateral, cavitation, progression \> 50% over a previous RX)\
10) Reasons suggesting inaccurate treatment compliance.

Mortality: was defined as death that occurred within 30 days of the diagnosis of CAP.

Evaluation {#Sec5}
----------

Clinical evaluation included: risk factors such as smoking and comorbidities (chronic lung disease, diabetes; chronic heart, renal or liver disease and history of malignancy). Findings on the clinical exam were recorded for each patient. Pneumonia severity index (PSI) \[[@CR18]\] was calculated .

Radiological assessment: the radiological patterns considered to support the diagnosis of pneumonia included the presence of: focal or multi-focal infiltrates, airspace infiltrates or an interstitial or miliary pattern. Pleural effusion without any parenchymal radiological findings was not included.

Microbiologic evaluation: urine samples collected in the emergency department or on the ward in the first 24 h to test for SPUAT (BinaxNOW ®, Portland, ME, and Alere Inc., Waltham, MA, USA) in accordance with the manufacturer's instructions. Blood cultures were drawn in all patients at admission. Culture of respiratory specimens for common aerobic bacteria were performed in a number of cases, but not systematically in all patients.

Blood analyses: all the hospitalized and some ambulatory patients entered into the study had blood drawn for white blood cell count and routine biologic analyses.

Demographic data (age and sex), the PSI score, site of care (ambulatory or admitted to the general ward or the ICU), presence of criteria for receiving pneumococcal vaccine, results of the blood culture, admission from a nursing home, past medical history including presence of comorbidities, smoking history and vaccination against SP were recorded.

Therapy and follow-up {#Sec6}
---------------------

Patients admitted to the study were treated per the criteria adopted by the attending physician and followed for up to 30 days. In brief, all patients received empiric antimicrobial therapy as early as possible and concordant with the National Guidelines, and fluid resuscitation with intravenous crystalloids for patients with hypotension.

Data analysis {#Sec7}
-------------

We carried out a nested case-control, cohort study; cases (the CAP2 patients) and controls (the CAP1 patients) were prospectively enrolled during the two periods of study. Cases were matched to controls for age ± 4 years, sex, and PSI score ± 10 points, allowing for the possibility of finding different etiologies and frequencies of pathogens. Results are expressed as mean and standard deviation for age, or as number and percentages for categorical variables. Age was assessed by the *t- test* and categorical variables were assessed by the chi square or Fisher exact test. The relative risk (RR) and 95% confidence interval (95%CI) of the cathegorical variables and their change over the time periods studied, were analyzed. A multivariate analysis, using a conditional logistic regression model, suggested for matched case-control studies \[[@CR19]\], with the dependent variable being the positivity of the SPUAT, was performed. Confounding factors including PSI class 5, having not received the pneumococcal vaccine and having not survived the episode of pneumonia, were used for adjustment to calculate the odds ratio (OR) and 95%CI. All data management and statistical analyses were performed using the SPSS 21 processor (SPSS Inc., Chicago, IL).

This study was approved by the ethics committee of the hospital, but patient-informed consent was considered unnecessary because of the observational nature of the study, but the study team explained the potential risks related to drawing blood, including the nature of potential risk of blood drawing.

Results {#Sec8}
=======

Clinical characteristics of the cohort {#Sec9}
--------------------------------------

A total of 498 patients with a clinical diagnosis of CAP made on either an outpatient basis or during the first 24 h of hospitalization were consecutively recruited. In all patients, at least one specimen for SPUAT and two sets of blood cultures were collected during their initial microbiological evaluation. Among these patients, 307 were recruited during the CAP1 period and 191 during the CAP2 period, respectively (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Distribution of the patients in the cohorts CAP1 and CAP2 in general and considering the approaches analyzing both cohorts, unmatched and matched. The unmatched patients, both from CAP1 and CAP2 cohorts, were excluded because they had no pair with comparable age, sex and PSI score. The number of patients excluded from the case-control analysis were 162 from the CAP1 and 46 from the CAP2 cohorts

Some significant differences were observed comparing the characteristics of the patients (unmatched) recruited during the two different periods, CAP1 and CAP2, including: age, 64.6 ± 21.2 vs. 70.3 ± 19.1 years old (*p* = 0.002); PSI score, 110.7 ± 39.8 vs 93.8 ± 41.1 (*p* \< 0.001); and percentages of smokers, 9.1% vs.17.3% (*p* = 0.007). The rates of hospitalization for each age group were 75.5% and 61.7%, for CAP1 and for CAP2, respectively (*p* = 0.001) (Table [2](#Tab2){ref-type="table"}, panel A). Also, we found significant differences among the percentage of patients who had received pneumococcal immunization, 4.2% vs 18.8% (*p* = 0.001) and the positivity of the SPUAT, 25.0% vs 9.5% (*p* = 0.001) respectively, comparing CAP1 and CAP2.Table 2Comparison of demographic and clinical characteristics among patients with CAP during the CAP1 and the CAP2 periods unmatched and matched (case control). Figures are means (±SD) and n (%). The *p* value and risk ratio (RR)PANEL A (UNMATCHED)PANEL B (MATCHED)VariableCAP1 (*n* = 307)CAP2 (*n* = 191)p valueCAP1 (*n* = 145)CAP2 (*n* = 145)p valueRRAge, year (±SD)64.6 ± 21.270.3 ± 19.10.00267.8 ± 20.467.7 ± 20.40.484Male Sex160 (58.6%)93 (48.7%)0.74974 (51.0)74 (51.0)1.0001.000PSI class 5106 (34.5%)43 (22.5%)\< 0.00137 (25.5%)33 (22.8%)0.5751.077Admitted from nursing home43 (14.0%)27 (14.1%)0.97212 (8.3%)23 (15.9%)0.0820.657Managed as outpatients75 (24.4%)73 (38.2%)0.00351 (35.12%54 (37.2%)0.7060.956Admitted to the hospital232 (75.5%)118 (61.7%)\< 0.00194 (64.8%)91 (62.8%)0.7160.968Admitted (general ward)176 (57.3%)100 (52.3%)0.40283 (57.2%77 (53.1%)0.4811.088Admitted (ICU)56 (18.2%)18 (9.4%)0.00711 (7.6%)14 (9.7%)0.5520.870Positive blood culture12 (3.9%)7 (3.7%)0.9547 (4.8%)6 (4.1%)0.7840.911Requiring mechanical ventilation16 (5.2%)6 (3.1%)0.0124 (2.8%)5 (3.4%)0.7480.886Pneumococcal immunization13 (4.2%)36 (18.8%)\< 0.0016 (4.1%)33 (22.7%)\< 0.0010.255Pneumococcal. vaccine Indication247 (80.4%)142 (74.3%)0.108109 (75.2%)103 (71.0%)0.4381.114Positive SPUAT81 (26.4%)18 (9.5%)\< 0.00134 (23.4%)12 (8.3%)\< 0.0012819Current smoker28 (9.1%)33 (17.3%)0.00715 (10.3%)20 (13.8%)0.3960.841Chronic lung disease91 (29.6%)41 (21.5%)0.04137 (25.3%)28 (19.3%)0.1841.186Cardiac disease68 (22.2%)38 (19.9%)0.55821 (14.5%)29 (20.1%)0.2430.813Diabetes29 (9.5%)22 (11.5%)0.46410 (6.9%13 (8.9%)0.7060.538Hepatic disease6 (1.9%)6 (3.1%)0.4122 (1.4%)3 (2.1%)0.6810.797Renal failure30 (10.8%)19 (9.9%)0.95110 (6.9%)5 (3.4%)0.1121.358Descesed64 (20.8%)30 (15.5%)0.14323 (15.9%)22 (15.2%)0.8701.026

Considering the indications for pneumococcal vaccination according to the national recommendations in Argentina (including age \> 65 years, comorbidities, splenectomy, and cerebrospinal fluid leakage); 247 (80.4%) patients had an indication for pneumococcal vaccination in the CAP1 and 142 (74.2%) patients, in the CAP2 time period.

Nested case-control study {#Sec10}
-------------------------

It was possible to successfully pair 145 CAP2 patients, age- (± 4 years), sex- and severity- (PSI score ± 5 points) matched, with 145 CAP1 control subjects. Forty-six cases were excluded because it was not possible to find a control among the CAP1 patients for them. The result of the comparison of CAP1 with CAP2 matched patients' findings in this nested case-control study is displayed in Table [2](#Tab2){ref-type="table"}, panel B.

Comparing CAP2 with CAP1 matched patients, most of the variables were not different. The exceptions were the increasing rate of pneumococcal immunization, 4.1% versus 22.7%, (RR = 0.2549, 95% confidence interval \[CI\] {0.1205 to 0.5390} 0.), *p* \< 0.001 and the declining rate of positive SPUAT, 23.4% vs. 8.3%, (RR = 1.6248, 95% CI \[1.3041 to 2.0243\]), *p* \< 0.001, comparing the two periods (Table [2](#Tab2){ref-type="table"}). This last finding represents a reduction in the RR of pneumococcal pneumonia that happened in the CAP2 period, compared with the CAP1 period.

Pneumococcal vaccination had been performed using the PPV23 vaccine in all cases during the CAP1 period. The same happened with the majority of those included in the CAP2 period, as PCV13 vaccine was approved for use in adults in 2012, and only indicated in adults older than 65 years-old by the CoNain in 2016, after the CAPiTA study was published. The CAPITA study demonstrated among this population that PCV13 was effective in preventing vaccine-type pneumococcal, bacteremic, and nonbacteremic CAP and vaccine type invasive pneumococcal disease, but not in preventing community-acquired pneumonia from any cause \[[@CR14], [@CR20]\].

Interestingly, although the positivity of the SPUAT was significantly different, showing a reduction in the RR of SP as a pathogen of pneumonia, the rate of bacteremia due to SP did not change during this time. All SP isolated in blood cultures were susceptible to penicillin (Clinical and Laboratory Standards Institute MIC breakpoints for patients without meningitis treated with intravenous penicillin were \< 2 μg/mL).

Mortality was also not different comparing CAP1 with CAP2 periods, in the matched population.

The result of the univariate and multivariate analyses using the positivity of the SPUAT as the dependent variable, the variables evaluated and their OR, the 95% CI, and the *p* values are displayed in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. These results confirm that, independent of the presence of a PSI risk class 5, of having a history of receving pneumococcal vaccine and of not surviving the episode of pneumonia, there were two factors that increased the chance of having the SPUAT positive: developing pneumonia during the CAP1 period in 2001--2002 (with an OR of 1.23) and having pneumococcal bacteremia (with an OR of 2.66).Table 3Conditional Logistic Regression model for matched cases and controls, Univariate Analysis, The odds ratio (OR), the 95% confidence index (CI 95%) and the *p* value are displayedVariableORCI 95%*p* valueCAP1 versus CAP2 Períod1.230.30 to 1.800.006Sex0.62−0.22 to 1.470.148Nursing Home−1.93−4.00 to 0.140.067PSI = 50.88−0.01 to 1.770.053CURB 650.26− 0.11 to 0.640.168Positive blood cultures2.801.26 to 4.35\< 0.001Positive sputum2.440.20 to 4.670.033Admitted to general ward1.630.60 to 2.660.002Outpatients−1.85−3.03 to −0.680.002Admitted to the ICU−0.19−1.60 to 1.230.800Decesed0.89−0.20 to 1.990.110Pneumococcal vaccination−0.25−1.46 to 0.950.680Table 4Conditional Logistic Regression model for matched cases and controls, Multivariate Analysis, showing that regardless of PSI class = 5, having received pneumococcal vaccine, and age (in addition to all the variables by which the individuals were matched), the only two factors that increased the chance of having positive SPUAT were belonging to the CAP1 (OR 2.66) cohort and having positive blood cultures (OR 2.66)VariableORCI 95%*p* valueCAP1 versus CAP2 Períod1.230.30 to 2.170.01Positive blood cultures2.660.80 to 4.520.005PSI = 50.005−0.013 to 0.0230.590Decesed−0.19−1.57 to 1.200.790Pneumococcal vaccination0.27−1.2 to 1.730.720

Discussion {#Sec11}
==========

The most important findings of our study are: (1) the relative risk of pneumococcal pneumonia, as per SPUAT positivity in a cohort of patients treated for CAP in a University Hospital (Hospital de Clínicas, University of Buenos Aires), during a 2 year (CAP2), was reduced overall to a ratio of 0.34 (*p* \< 0.001), compared with a control cohort, treated 14 years earlier (CAP1), matched by age, sex and severity of illness; (2) the f history of pneumococcal vaccination (mainly PPV23) among the CAP2 group of patients increased overall to a ratio of 0.55 (*p* \< 0.001), even though the percentage of patients indicated to receive the vaccination did not change. In addition, rates of pneumococcal bacteremia and overall mortality did not change over the two time periods. Reported mortality was comparable to the rates observed in the UK (Chalmers JD, et al\...) and US (Morril HJ, et al) \[[@CR21], [@CR22]\]. Out matched, nested case-control methods run the risk of over-matching, and thus we also analyzed the positivity of the SPUAT observed in this study using a multivariate method. This analysis was based on the linear logistic model (conditional logistic model), recomended for the analysis of case-control studies with pairwise matching. This technique enabled us to investigate the effect of several variables simultaneously in the analysis, while allowing for the matched design. This multivariate analysis demonstrated that only two factors increased the chance of having a positive positive SPUAT: developing pneumonia in the CAP 1 period (OR = 1.23) and having pneumococcal bacteremia (OR = 2.66). The latter was expected, but confirms the robustness of our analysis.

The SPUAT test, provides results in 15 min, detecting the C-polysaccharide cell wall antigen common to all SP strains \[[@CR23]\]. The sensitivity and specificity of the SPUAT have been evaluated and most studies demonstrated high specificity near 100% and moderate to high sensitivity. Horita et al., found in a meta-analysis, a pooled specificity of 0.75 and a pooled sensitivity was 0.95. This high sensitivity and specificity make SPUAT a useful tool in clinical practice to predict negatively or positively the role of SP in the etiology of CAP. Ortega et al. found evidence that links the degree of the SPUAT positivity to the severity of the pneumonia \[[@CR24]\]. Some studies published between 2001 and 2007 in patients with a clinical diagnosis of CAP showed that SPUAT was positive in a range between 16 and 33% of patients \[[@CR25]--[@CR28]\].

The introduction of PCV7 into the infant immunization programs in developed countries beginning in 2006, was highly effective in reducing the incidence of invasive and non-invasive pneumococcal disease. Rodrigo et al., beginning in 2008, conducted a 5-year prospective cohort study of adults admitted to hospital with CAP in Nottingham, UK \[[@CR15]\]; they observed a reduction in the incidence of the number of adult patients hospitalized for pneumococcal CAP \[incidence rate ratio (IRR) per year 0.84, 95% CI 0.80--0.89; *p* \< 0.001\] over the 5-year period of the study. The incidence of CAP due to serotypes included in the PCV7 declined by 88% (IRR 0.12, 95% CI 0.08--0.20; *p* \< 0.001), and CAP due to the additional 6 serotypes in PCV13 declined by 30% (IRR 0.70, 95% CI 0.51--0.96; *p* = 0.024). This study and other previous studies described the finding of so-called herd immunity, reducing the incidence of pneumococcal pneumonia in children and adults, after the introduction of PCV7 and PCV13 into the infant immunization programs \[[@CR29], [@CR30]\]. Other authors found that although PCV13 protects against key serotypes that increased after routine immunization with the PCV7, its potential for herd immunity and serotype replacement is uncertain \[[@CR31]--[@CR37]\]. In Argentina, the percentages of coverages for the 1st and 3rd doses of PCV13 have been appropriate and comparable with the coverage observed in developed countries such as the United States, after its introduction in 2012. Our study suggested a potential benefit to adults, of the immunization with pneumococcal vaccine in children, leading to a dramatic decline in non-invasive pneumooccal CAP, diagnosed by SPUAT, but no change in bacteremic pneumococcal CAP.

This study has several limitations, including: the diagnosis of pneumococcal pneumonia was based on the positivity of the SPAUT, a methodology that highly specific, but can produce between a 25% and 42.1% rate of false negatives \[[@CR8]--[@CR11]\]. Blood cultures were performed to all patients, but respiratory cultures and/or serotyping were not available for all patients. Also, we could not analyze the effect of concordant therapy, because this was not recorded in all patients in the CAP1 cohort.

Among the strengths of our study, is our comparison of two cohorts, one treated after the implementation of PCV vaccination in children in the calendar in 2012, with another comparable cohort treated before the implementation of this pneumococcal vaccine, allowing us to compare the frequency of pneumococcal pneumonia, including by multivariate analysis.

Conclusions {#Sec12}
===========

The result of this comparison demonstrated that the RR of pneumococcal pneumonia, diagnosed as per SPUAT positivity, was reduced in more recent years, leading us to speculate about possible explanations. The frequency of SP as the causative microorganism of CAP was reduced to a ratio of 0.34, compared with the control cohort, 23.4% vs 8.3% (*p* \< 0.001), although there was no change in the frequency of bacteremic pneumococcal pneumonia. The introduction of pneumococcal vaccine might account for a decline in pneumococcal pneumonia by either inducing immunity in immunized at risk patients or by its herd immunity impact of childhood vaccination on the community, but this could be confirmed only in studies demonstrating a reduction of the serotypes represented by the vaccine.
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